Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03895853 · ClinicalTrials.gov registry record · Phase 2
Early Metabolic Resuscitation for Septic Shock
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03895853: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03895853 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03895853, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock. Early metabolic resuscitation is made of large doses of glucose, protein, and essential metabolic molecules that may help lower the effects of septic shock on the body. Giving patients early metabolic resuscitation in combination with standard of care may work better in reducing multi-organ dysfunction syndrome in patients with septic shock compared to standard of care alone.
Interventions
- OTHER Best Practice
- DIETARY_SUPPLEMENT early metabolic resuscitation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03895853
The ClinicalTrials.gov registry entry for NCT03895853 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Best Practice is the first listed.
NCT03895853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03895853 about?
NCT03895853 is a clinical study titled "Early Metabolic Resuscitation for Septic Shock". This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock. Early metabolic resuscitation is made of large doses of glucose, protein, and essential metabolic molecules that may help lower the effects of septic sh...
What is the current status of trial NCT03895853?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-10-04. Estimated completion is 2020-05-04.
What interventions are being tested in trial NCT03895853?
The interventions under investigation include: Best Practice (OTHER), early metabolic resuscitation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03895853?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.